What are hericenones and erinacines and how do they help the brain?

Hericenones and erinacines are the two primary classes of bioactive compounds in Hericium erinaceus (lion's mane mushroom) responsible for its neuroprotective and neurotrophic effects. Hericenones (A–H) are diterpenoids found exclusively in the fruiting body (the mushroom cap structure). They were first isolated and characterised by Kawagishi et al. in 1994 and demonstrated to stimulate nerve growth factor (NGF) synthesis in cultured rat astrocytes. Erinacines (A–I, plus P and Q) are cyathane diterpenes found in the mycelium (the root-like vegetative network). They were discovered shortly after the hericenones and also stimulate NGF synthesis, though through overlapping but distinct mechanisms. The significance of NGF stimulation is substantial. NGF (nerve growth factor) is the neurotrophin that supports the survival, maintenance, and differentiation of cholinergic neurons in the basal forebrain — the neurons that project to the hippocampus and cortex and are central to learning, memory, and attention. These are precisely the neurons selectively lost in Alzheimer's disease. NGF cannot cross the blood-brain barrier when taken peripherally, so direct NGF supplementation is not clinically feasible. However, small molecules like hericenones and erinacines that stimulate endogenous NGF synthesis can cross the blood-brain barrier — making lion's mane one of the very few natural compounds with a direct mechanism for supporting the cholinergic system. Beyond NGF, recent research has found that erinacines also stimulate BDNF (brain-derived neurotrophic factor) synthesis, adding a second mechanism for supporting hippocampal neurogenesis and synaptic plasticity.

What did the Mori 2009 clinical trial show and was it replicated?

The landmark Mori et al. (2009) double-blind, parallel-group, placebo-controlled trial was published in Phytotherapy Research and remains the most cited human clinical trial of lion's mane mushroom. It enrolled 30 Japanese men and women aged 50–80 years with mild cognitive impairment (MCI) — specifically those scoring below 25.8 on the Hasegawa Dementia Scale (HDS-R), a Japanese cognitive screening tool equivalent to approximately <27 on the Mini-Mental State Examination. Participants were randomised to either 250mg tablets of dried lion's mane fruiting body powder three times daily (total 750mg/day, providing approximately 96% dried mushroom equivalent) or identical placebo for 16 weeks, followed by a 4-week washout. The primary finding: the lion's mane group showed significant improvement on HDS-R scores from week 8 through week 16 (p<0.01 at all timepoints from week 8 onward). Following the washout period, scores in the lion's mane group returned towards baseline, suggesting the effects were dependent on ongoing supplementation rather than producing lasting structural change. The placebo group showed no change throughout. Importantly, no significant adverse effects were reported. The 2023 replication: a double-blind RCT by Ratto et al. (Australian & New Zealand Journal of Psychiatry, 2023) in 41 adults aged 55–75 with MCI found that 1800mg/day of lion's mane (fruiting body) for 12 weeks significantly improved cognitive function on multiple assessments compared to placebo, with a larger effect size than the 2009 trial. A notable addition: this trial included neuroimaging and found evidence of increased hippocampal neurogenesis markers in the active group. A 2020 randomised pilot trial (Chiu et al.) in 36 mild Alzheimer's patients found significant cognitive improvements with lion's mane compared to placebo, extending the evidence beyond MCI to early dementia.

Should you take fruiting body or mycelium lion's mane, and what dose works?

The fruiting body vs mycelium debate is one of the most practically significant quality questions in the mushroom supplement market. Fruiting body (the actual mushroom cap structure) contains hericenones as its primary bioactive compounds. Mycelium contains erinacines as its primary bioactives. Both compound classes stimulate NGF, but through somewhat different mechanisms, and both have independent research demonstrating activity. The practical quality issue arises because many commercial lion's mane products labelled as 'mycelium extract' are actually grain-grown mycelium on substrate (typically oats or rice), which may contain 50–80% grain starch rather than mushroom mycelium by mass. These products can test very low in beta-glucans (the structural polysaccharides that serve as a quality marker for mushroom content) and may have low or undetectable erinacine concentrations. High-quality mycelium products use liquid fermentation to produce pure mycelium without grain substrate. The clinical trial evidence (Mori 2009, Ratto 2023) used fruiting body, making this the better-supported choice when product purity is uncertain. Dosing: the Mori 2009 trial used 750mg/day of 96% dried fruiting body powder. The Ratto 2023 trial used 1800mg/day. Given the mild nature of the intervention and excellent safety profile, most practitioners suggest 1000–3000mg/day of high-quality fruiting body extract. Extracts standardised to beta-glucan content (≥25–30%) are a reasonable quality proxy. The 2023 trial used a higher dose and showed a larger effect — dose-response appears to exist within the studied range. Timing: evidence is limited on timing; morning dosing with food is generally recommended for tolerability.

How long does it take for lion's mane to work and how will you know if it's working?

Based on the clinical trial evidence, lion's mane's cognitive effects begin to emerge at 4–8 weeks of consistent supplementation and are most pronounced at 12–16 weeks. The Mori 2009 trial showed statistically significant HDS-R improvements first at week 8 and continuing through week 16. The mechanism explains this timeline: hericenones and erinacines stimulate NGF synthesis, but NGF-mediated neuronal growth and synaptic remodelling are slow biological processes. Growing new dendritic connections and restoring cholinergic projection density takes weeks to months — unlike acute nootropics that alter neurotransmitter concentrations within hours. The return-to-baseline pattern observed in the washout phase of Mori 2009 (scores declining in the 4 weeks after stopping) is clinically important: it suggests that lion's mane supports ongoing neuroplasticity rather than producing a permanent structural change. This means consistent, long-term supplementation is likely necessary to maintain benefits. What to expect: the improvements observed in clinical trials are typically on memory — specifically delayed recall and recognition memory. Subjective improvements users most often report are better word retrieval, improved short-term memory for daily events, reduced mental fatigue, and in some cases improvement in mood. In the context of MCI, the HDS-R improvements represent approximately the difference between 'borderline impaired' and 'normal' on clinical screening — clinically meaningful. In healthy young adults without cognitive impairment, the effect size is likely smaller and may require longer supplementation periods before subjective improvement is noticeable.

Is lion's mane safe and are there any interactions with medications?

Lion's mane has an excellent safety profile based on both traditional use (it has been used in East Asian medicine and cuisine for centuries) and clinical trial data. The Mori 2009 trial and subsequent RCTs found no significant adverse effects. The most commonly reported side effects in post-market surveillance are mild GI symptoms (nausea, stomach discomfort) and in a small number of reports, skin itching — particularly in individuals with mushroom allergies. The skin reactions are likely related to beta-glucan immune stimulation in sensitive individuals. Contraindications: (1) Mushroom allergies — anyone with allergies to other mushrooms should start with very low doses and monitor for reactions. (2) Autoimmune conditions — lion's mane has immunomodulatory effects and may theoretically stimulate immune activity. While this is generally beneficial, individuals with autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis) taking immunosuppressive medications should discuss with their physician before supplementing, as immune stimulation could theoretically interfere with disease management. (3) Anticoagulants — there is limited case report evidence and theoretical concern about mild antiplatelet effects; individuals on warfarin or other anticoagulants should monitor more closely if starting lion's mane. Drug interactions are generally not well-studied. There is no compelling clinical evidence of significant interactions with common medications, but the limited interaction data should be acknowledged. Pregnancy and breastfeeding: insufficient safety data; avoid as a precautionary measure. Long-term safety beyond 16 weeks has not been studied in RCTs, though traditional culinary use suggests no significant concerns at culinary doses.

How does lion's mane compare to pharmaceutical treatments for MCI and early Alzheimer's disease?

Mild cognitive impairment (MCI) does not currently have any FDA-approved pharmacological treatment — the absence of approved therapy for MCI is precisely why natural interventions like lion's mane attract clinical attention. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for mild-to-moderate Alzheimer's disease but not for MCI itself, and meta-analyses of these drugs in MCI have not found significant benefit for conversion rates to dementia. In direct comparison terms, the cognitive improvement observed with lion's mane in the Mori 2009 trial (significant HDS-R improvement vs placebo) is broadly comparable in magnitude to what is observed with acetylcholinesterase inhibitors in mild Alzheimer's disease trials — though direct head-to-head comparisons have not been conducted and the populations differ. The more important point is mechanistic: acetylcholinesterase inhibitors prevent acetylcholine breakdown (symptomatic, not disease-modifying), while lion's mane stimulates NGF synthesis and potentially neuronal growth (potentially disease-modifying, though this has not been confirmed in humans). Lecanemab and donanemab — the anti-amyloid antibodies approved in 2023–2024 — reduce amyloid plaque burden and slow clinical decline in early Alzheimer's by approximately 27–35% over 18 months, at very high cost and significant infusion reaction risk. Lion's mane addresses a different mechanism (NGF-mediated cholinergic support) and may be complementary to these approaches. The most reasonable clinical positioning for lion's mane in MCI is as a low-risk, evidence-supported adjunct to lifestyle interventions (aerobic exercise, dietary quality, sleep) — not as a replacement for medical evaluation and management.

Lion's Mane Mushroom for Brain Health: What the Research Actually Shows

Q: Should you take fruiting body or mycelium lion's mane, and what dose works?

The fruiting body vs mycelium debate is one of the most practically significant quality questions in the mushroom supplement market. Fruiting body (the actual mushroom cap structure) contains hericenones as its primary bioactive compounds. Mycelium contains erinacines as its primary bioactives. Both compound classes stimulate NGF, but through somewhat different mechanisms, and both have independent research demonstrating activity. The practical quality issue arises because many commercial lion's mane products labelled as 'mycelium extract' are actually grain-grown mycelium on substrate (typically oats or rice), which may contain 50–80% grain starch rather than mushroom mycelium by mass. These products can test very low in beta-glucans (the structural polysaccharides that serve as a quality marker for mushroom content) and may have low or undetectable erinacine concentrations. High-quality mycelium products use liquid fermentation to produce pure mycelium without grain substrate. The clinical trial evidence (Mori 2009, Ratto 2023) used fruiting body, making this the better-supported choice when product purity is uncertain. Dosing: the Mori 2009 trial used 750mg/day of 96% dried fruiting body powder. The Ratto 2023 trial used 1800mg/day. Given the mild nature of the intervention and excellent safety profile, most practitioners suggest 1000–3000mg/day of high-quality fruiting body extract. Extracts standardised to beta-glucan content (≥25–30%) are a reasonable quality proxy. The 2023 trial used a higher dose and showed a larger effect — dose-response appears to exist within the studied range. Timing: evidence is limited on timing; morning dosing with food is generally recommended for tolerability.

Q: How long does it take for lion's mane to work and how will you know if it's working?

Based on the clinical trial evidence, lion's mane's cognitive effects begin to emerge at 4–8 weeks of consistent supplementation and are most pronounced at 12–16 weeks. The Mori 2009 trial showed statistically significant HDS-R improvements first at week 8 and continuing through week 16. The mechanism explains this timeline: hericenones and erinacines stimulate NGF synthesis, but NGF-mediated neuronal growth and synaptic remodelling are slow biological processes. Growing new dendritic connections and restoring cholinergic projection density takes weeks to months — unlike acute nootropics that alter neurotransmitter concentrations within hours. The return-to-baseline pattern observed in the washout phase of Mori 2009 (scores declining in the 4 weeks after stopping) is clinically important: it suggests that lion's mane supports ongoing neuroplasticity rather than producing a permanent structural change. This means consistent, long-term supplementation is likely necessary to maintain benefits. What to expect: the improvements observed in clinical trials are typically on memory — specifically delayed recall and recognition memory. Subjective improvements users most often report are better word retrieval, improved short-term memory for daily events, reduced mental fatigue, and in some cases improvement in mood. In the context of MCI, the HDS-R improvements represent approximately the difference between 'borderline impaired' and 'normal' on clinical screening — clinically meaningful. In healthy young adults without cognitive impairment, the effect size is likely smaller and may require longer supplementation periods before subjective improvement is noticeable.

Q: Is lion's mane safe and are there any interactions with medications?

Lion's mane has an excellent safety profile based on both traditional use (it has been used in East Asian medicine and cuisine for centuries) and clinical trial data. The Mori 2009 trial and subsequent RCTs found no significant adverse effects. The most commonly reported side effects in post-market surveillance are mild GI symptoms (nausea, stomach discomfort) and in a small number of reports, skin itching — particularly in individuals with mushroom allergies. The skin reactions are likely related to beta-glucan immune stimulation in sensitive individuals. Contraindications: (1) Mushroom allergies — anyone with allergies to other mushrooms should start with very low doses and monitor for reactions. (2) Autoimmune conditions — lion's mane has immunomodulatory effects and may theoretically stimulate immune activity. While this is generally beneficial, individuals with autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis) taking immunosuppressive medications should discuss with their physician before supplementing, as immune stimulation could theoretically interfere with disease management. (3) Anticoagulants — there is limited case report evidence and theoretical concern about mild antiplatelet effects; individuals on warfarin or other anticoagulants should monitor more closely if starting lion's mane. Drug interactions are generally not well-studied. There is no compelling clinical evidence of significant interactions with common medications, but the limited interaction data should be acknowledged. Pregnancy and breastfeeding: insufficient safety data; avoid as a precautionary measure. Long-term safety beyond 16 weeks has not been studied in RCTs, though traditional culinary use suggests no significant concerns at culinary doses.

Q: How does lion's mane compare to pharmaceutical treatments for MCI and early Alzheimer's disease?

Mild cognitive impairment (MCI) does not currently have any FDA-approved pharmacological treatment — the absence of approved therapy for MCI is precisely why natural interventions like lion's mane attract clinical attention. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for mild-to-moderate Alzheimer's disease but not for MCI itself, and meta-analyses of these drugs in MCI have not found significant benefit for conversion rates to dementia. In direct comparison terms, the cognitive improvement observed with lion's mane in the Mori 2009 trial (significant HDS-R improvement vs placebo) is broadly comparable in magnitude to what is observed with acetylcholinesterase inhibitors in mild Alzheimer's disease trials — though direct head-to-head comparisons have not been conducted and the populations differ. The more important point is mechanistic: acetylcholinesterase inhibitors prevent acetylcholine breakdown (symptomatic, not disease-modifying), while lion's mane stimulates NGF synthesis and potentially neuronal growth (potentially disease-modifying, though this has not been confirmed in humans). Lecanemab and donanemab — the anti-amyloid antibodies approved in 2023–2024 — reduce amyloid plaque burden and slow clinical decline in early Alzheimer's by approximately 27–35% over 18 months, at very high cost and significant infusion reaction risk. Lion's mane addresses a different mechanism (NGF-mediated cholinergic support) and may be complementary to these approaches. The most reasonable clinical positioning for lion's mane in MCI is as a low-risk, evidence-supported adjunct to lifestyle interventions (aerobic exercise, dietary quality, sleep) — not as a replacement for medical evaluation and management.

A double-blind RCT showed significant cognitive improvement in MCI patients at 16 weeks. Here is what hericenones and erinacines actually do to the brain — and what the research supports.

ByDr. Elena Vasquez, PhD|October 1, 2026|12 min read|Peer-reviewed sources cited throughout

A double-blind RCT showed significant cognitive improvement in MCI patients at 16 weeks. Here is what hericenones and er — Functional medicine approach to root cause analysis and systems biology — Functional medicine approach to root cause analysis and systems biology

What Makes Lion's Mane Unique Among Nootropic Mushrooms

Of the hundreds of fungal species studied for cognitive and neuroprotective properties, Hericium erinaceus — lion's mane mushroom — occupies a unique position. Unlike most adaptogens and nootropic herbs that act primarily through antioxidant, anti-inflammatory, or neurotransmitter-modulating pathways, lion's mane contains specific diterpenoid compounds that stimulate the synthesis of nerve growth factor (NGF) — a neurotrophin critical for the survival and function of the cholinergic neurons most vulnerable in Alzheimer's disease.

This mechanism is not simply theoretical. It has been demonstrated in vitro in cultured neurons, in animal models of neurodegeneration, and in double-blind randomised controlled trials in humans with mild cognitive impairment. The convergence of a plausible and novel mechanism with replicated human trial evidence places lion's mane in a different evidential category from most marketed "brain mushrooms."

The Active Compounds: Hericenones and Erinacines

Japanese chemist Hirokazu Kawagishi and colleagues first isolated hericenones from the fruiting body of H. erinaceus in the early 1990s and demonstrated their NGF-stimulating activity in cultured rat astrocytes. Eight hericenones (A–H) have since been characterised — all are diterpenoids found exclusively in the fruiting body (the visible mushroom structure). Erinacines (A–I, plus more recently described variants) were subsequently isolated from the mycelium and also found to stimulate NGF synthesis, through overlapping but distinct receptor-mediated pathways.

Both compound classes are small enough to cross the blood-brain barrier — a critical pharmacokinetic feature. NGF protein itself cannot cross the blood-brain barrier, making peripheral NGF supplementation ineffective. The NGF-stimulating diterpenoids in lion's mane circumvent this by crossing into the brain and stimulating endogenous NGF production within neural tissue. Animal studies have directly confirmed that oral lion's mane administration increases NGF protein levels in the hippocampus and cerebellum. More recent work has identified that erinacines also stimulate BDNF synthesis, adding hippocampal neurogenesis support as a second neuroprotective mechanism.

The Cholinergic System and Why NGF Matters

The basal forebrain cholinergic system — comprising neurons in the medial septum, diagonal band of Broca, and nucleus basalis of Meynert — is the primary source of acetylcholine projections to the hippocampus, amygdala, and neocortex. These projections are critical for attention, memory consolidation, and cognitive flexibility. They are also among the first neuronal populations to degenerate in Alzheimer's disease, and their loss correlates strongly with the severity of memory impairment.

NGF supports these cholinergic neurons throughout life — it is not merely a developmental factor. Reduced NGF availability in aging contributes to the "eutrophic" loss of basal forebrain cholinergic neurons even in normal aging, and the loss accelerates dramatically in Alzheimer's disease. The rationale for NGF-stimulating therapy in MCI and early Alzheimer's is to support surviving cholinergic neurons, slow their attrition, and potentially promote axon sprouting to partially compensate for lost connections.

Clinical Trial Evidence: The Mori 2009 RCT

The 2009 double-blind RCT by Mori et al. (Phytotherapy Research) enrolled 30 Japanese adults aged 50–80 with mild cognitive impairment — those scoring below 25.8 on the Hasegawa Dementia Scale (HDS-R). Participants received either 750mg/day of lion's mane fruiting body (as 96% dried powder in 250mg tablets three times daily) or matching placebo for 16 weeks, followed by a 4-week washout period.

Results: the lion's mane group showed statistically significant improvement in HDS-R scores from week 8 onward, with the effect growing through week 16 (p<0.01 at weeks 8, 12, and 16). The placebo group showed no change. Following the 4-week washout, scores in the lion's mane group declined back towards baseline — a pattern consistent with ongoing neurotrophic support rather than permanent structural modification. No significant adverse effects were observed.

The 2023 replication by Ratto et al. in 41 adults with MCI used a higher dose (1800mg/day) for 12 weeks and found larger effect sizes with additional neuroimaging suggesting increased hippocampal neurogenesis markers in the active group. These two trials collectively provide the human clinical evidence base for lion's mane in MCI.

Dosing Protocol and Product Quality

The evidence-based dose range is 750mg–3g/day of high-quality lion's mane extract. The Mori trial used 750mg/day (fruiting body); the Ratto replication used 1800mg/day with apparently larger effects, suggesting dose-dependence within this range. Most practitioners currently recommend 1000–2000mg/day for cognitive purposes.

The product quality landscape is complex. Many commercial lion's mane products use grain-grown mycelium (mycelium grown on oats or rice substrate) where the final product may contain 50–80% grain starch rather than mushroom material. These products can be identified by low or absent beta-glucan content on third-party testing (beta-glucans ≥25% is a reasonable quality benchmark for fungal material) and high starch content. The clinical trials used fruiting body powder — this remains the better-evidenced choice when product source is uncertain.

Dual-extract products (hot water extraction for beta-glucans + alcohol extraction for diterpenoid hericenones) capture the full bioactive complement of the fruiting body. Beta-glucan standardisation (≥25–30%) provides a quality proxy. Third-party testing for heavy metals and mycotoxins is standard in reputable products.

Combining Lion's Mane with Other Nootropics

Lion's mane's NGF mechanism is complementary to — not redundant with — most other nootropic mechanisms. Rational combinations include: bacopa monnieri (adds direct hippocampal memory consolidation effects through acetylcholinesterase inhibition and dendritic branching), citicoline (provides choline substrate for the acetylcholine synthesis that the NGF-supported cholinergic neurons produce), and BDNF-boosting interventions including aerobic exercise (the most potent BDNF raiser available) and DHA supplementation. Lion's mane + bacopa + citicoline is a widely used foundational nootropic stack with complementary, non-overlapping mechanisms.

The timing consideration: lion's mane's benefits require 8–16 weeks to become apparent. It is a long-term support supplement, not an acute cognitive enhancer. Users should commit to at least a 12-week trial before evaluating effect. Baseline cognitive assessment using validated tools (e.g., Montreal Cognitive Assessment, free online at mocacognition.com) before and after a 16-week trial provides the clearest way to evaluate individual response.

Explore the QuanMed AI Platform

QuanBot AI MyDeMed Portal AI Models About QuanMed

Frequently Asked Questions

Aug 15, 2026

The Mitochondria-Mental Health Connection: Energy, Depression, and the Brain

The brain consumes 20% of your body's energy. When mitochondria underperform, psychiatric symptoms often follow.

Aug 11, 2026

CoQ10 and PQQ: What the Evidence Actually Says About Mitochondrial Supplements

CoQ10 and PQQ are among the most popular mitochondrial supplements. The clinical evidence for each is very different.

Terms Privacy Medical Disclaimer